Showing 5031-5040 of 5621 results for "".
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval-2/2477164/Staar Surgical announced that the FDA, in a letter dated December 6, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN To
- Bausch + Lomb Introduces Envista Toric MX60ET IOL With Stableflex Technologyhttps://modernod.com/news/bausch-lomb-introduces-envista-toric-mx60et-iol-with-stableflex-technology/2477160/Bausch + Lomb has introduced the enVista toric MX60ET hydrophobic acrylic IOL with StableFlex technology. Bausch + Lomb says the MX60ET provides improved material properties to deliver enhanced optic recovery following delivery. Like the enVista toric MX60T, the MX60ET offers a glistening free op
- AI Diagnostics Company IDx Announces New Appointments to its Executive Leadership Teamhttps://modernod.com/news/ai-diagnostics-company-idx-announces-new-appointments-to-its-executive-leadership-team/2477153/IDx Technologies announced several new appointments to its executive leadership team to accelerate product development and scale operations to accommodate increased market adoption of IDx-DR, according to a company news release. IDx-DR is an FDA-authorized autonomous AI system that detects diabet
- Sight Sciences Appoints Erica Rogers to its Board of Directorshttps://modernod.com/news/sight-sciences-appoints-erica-rogers-to-its-board-of-directors/2477149/Sight Sciences announced the appointment of Erica Rogers to the company’s board of directors. Ms. Rogers, President and CEO of Silk Road Medical, is an experienced leader and entrepreneur in the medical device industry. She most recently led Silk Road Medical through FDA approval of
- Smartphone App Spots Undiagnosed Symptomatic Dry Eye, Helps Identify Risk Factorshttps://modernod.com/news/smartphone-app-spots-undiagnosed-symptomatic-dry-eye-helps-identify-risk-factors/2477144/A smartphone app can identify people with undiagnosed symptomatic dry eye and identify factors linked with the condition, according to a new crowd-sourced study, Reuters reported. “We identified risk factors possibly associated with undiagnosed symptomatic dry eye, including younger
- Nicox Signs Agreement for Zerviate in South Koreahttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-south-korea/2477143/Nicox announced the signature of an exclusive license agreement with Samil Pharmaceutical for the development and commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea. Samil Pharmaceutical i
- Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-part-1-of-adaptive-phase-3-renew-trial-in-dry-eye-disease/2477138/Aldeyra Therapeutics announced positive topline results from Part 1 of the adaptive phase 3 RENEW trial of topical ocular reproxalap in patients with dry eye disease, according to a company news release. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate
- Mark McGrath to Headline Celebration at Optometry’s Meeting 2020https://modernod.com/news/mark-mcgrath-to-headline-celebration-at-optometrys-meeting-2020/2477126/The American Optometric Association has announced that it is celebrating the decade of the 90s at its annual Optometry’s Meeting, June 24-28, in National Harbor, Maryland/Washington, D.C. “Mark McGrath’s ’90s Experience” will headline the closing Celebration o